ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
Dow Jones
38,686.32
1.51%
US Dollar vs MXN
16.99024
-0.30%
Brent Oil
81.295
0.00%
Bitcoin
67,708.17
0.34%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Rexahn Pharmaceuticals Inc (REXN)

  7. Rexahn Pharmaceuticals Inc (REXN) Noticias

REXN

Rexahn Pharmaceuticals (REXN)

Rexahn Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:REXN
FechaHoraFuenteTítuloSímboloCompañía
14/06/202315:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:REXNRexahn Pharmaceuticals Inc
08/06/202317:49Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REXNRexahn Pharmaceuticals Inc
15/05/202307:23Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:REXNRexahn Pharmaceuticals Inc
01/05/202315:16Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:REXNRexahn Pharmaceuticals Inc
01/05/202315:13Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:REXNRexahn Pharmaceuticals Inc
05/04/202316:05Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:REXNRexahn Pharmaceuticals Inc
30/03/202316:08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:REXNRexahn Pharmaceuticals Inc
14/02/202313:04Edgar (US Regulatory)Annual Statement of Changes in Beneficial Ownership (5)NASDAQ:REXNRexahn Pharmaceuticals Inc
10/06/202215:17Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:REXNRexahn Pharmaceuticals Inc
17/05/202215:38Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:REXNRexahn Pharmaceuticals Inc
14/02/202215:20Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:REXNRexahn Pharmaceuticals Inc
09/06/202116:20Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:REXNRexahn Pharmaceuticals Inc
07/06/202115:21Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:REXNRexahn Pharmaceuticals Inc
07/06/202115:06Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:REXNRexahn Pharmaceuticals Inc
16/02/202105:31Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:REXNRexahn Pharmaceuticals Inc
11/02/202115:44Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:REXNRexahn Pharmaceuticals Inc
04/02/202106:28Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:REXNRexahn Pharmaceuticals Inc
30/11/202014:44Edgar (US Regulatory)Sec Staff Action/letter (sec Staff)NASDAQ:REXNRexahn Pharmaceuticals Inc
10/11/202009:09GlobeNewswire Inc.Ocuphire to Participate in Upcoming Virtual HCW Conference in NovemberNASDAQ:REXNRexahn Pharmaceuticals Inc
05/11/202010:50GlobeNewswire Inc.Rexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire PharmaNASDAQ:REXNRexahn Pharmaceuticals Inc
02/11/202008:00GlobeNewswire Inc.Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire PharmaNASDAQ:REXNRexahn Pharmaceuticals Inc
20/10/202007:56Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:REXNRexahn Pharmaceuticals Inc
02/10/202008:27Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:REXNRexahn Pharmaceuticals Inc
30/09/202008:19Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:REXNRexahn Pharmaceuticals Inc
24/07/202020:21PR Newswire (US)SHAREHOLDER ALERT: WeissLaw LLP Reminds DCOM and REXN Shareholders About Its Ongoing InvestigationsNASDAQ:REXNRexahn Pharmaceuticals Inc
17/07/202014:15PR Newswire (US)INVESTIGATION ALERT: Halper Sadeh LLP is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are ...NASDAQ:REXNRexahn Pharmaceuticals Inc
07/07/202020:07PR Newswire (US)SHAREHOLDER ALERT: WeissLaw LLP Reminds REXN and DLMV Shareholders About Its Ongoing InvestigationsNASDAQ:REXNRexahn Pharmaceuticals Inc
06/07/202015:09Edgar (US Regulatory)Securities Registration: Business Combination (s-4)NASDAQ:REXNRexahn Pharmaceuticals Inc
29/06/202015:47PR Newswire (US)Rexahn Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Merger Of Rexahn Pharmaceuticals, Inc....NASDAQ:REXNRexahn Pharmaceuticals Inc
26/06/202020:03PR Newswire (US)SHAREHOLDER ALERT: WeissLaw LLP Investigates Rexahn Pharmaceuticals, Inc.NASDAQ:REXNRexahn Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:REXN

Su Consulta Reciente

EU
FR0014001HO8
BPCE Master Home Loans B...
NASDAQ
THCPW
Thunder Bridge Captial P...
TG
MSF
Microsoft
COIN
ZKUST
Poriot
EU
F549T
F549T
COIN
PUBEEUSD
PubeCoin
USOTC
EDRWY
Electric Power Developem... (PK)
COIN
PEECHETH
Peach.Finance
USOTC
CHFI
China Finance (CE)
NASDAQ
PRTH
Priority Technology
COIN
QUBTGBP
Cubechain
BOV
PETRV311
PETRV311 Ex:28,37
USOTC
GCGJ
Guochun (PK)
USOTC
JAPPF
Japan Systems Techniques (PK)
COIN
MEVVKRW
MEVerse
USOTC
CHTH
CNL Healthcare Properties (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados